221 related articles for article (PubMed ID: 16416302)
1. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
Polasek TM; Miners JO
Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
[TBL] [Abstract][Full Text] [Related]
2. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
Ito K; Ogihara K; Kanamitsu S; Itoh T
Drug Metab Dispos; 2003 Jul; 31(7):945-54. PubMed ID: 12814973
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
Yamazaki H; Shimada T
Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
[TBL] [Abstract][Full Text] [Related]
4. Formation in vitro of an inhibitory cytochrome P450 x Fe2+-metabolite complex with roxithromycin and its decladinosyl, O-dealkyl and N-demethyl metabolites in rat liver microsomes.
Yamazaki H; Shimada T
Xenobiotica; 1998 Oct; 28(10):995-1004. PubMed ID: 9849646
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.
Greenblatt DJ; von Moltke LL; Harmatz JS; Counihan M; Graf JA; Durol AL; Mertzanis P; Duan SX; Wright CE; Shader RI
Clin Pharmacol Ther; 1998 Sep; 64(3):278-85. PubMed ID: 9757151
[TBL] [Abstract][Full Text] [Related]
6. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.
Kanamitsu S; Ito K; Green CE; Tyson CA; Shimada N; Sugiyama Y
Pharm Res; 2000 Apr; 17(4):419-26. PubMed ID: 10870985
[TBL] [Abstract][Full Text] [Related]
7. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.
Wang RW; Newton DJ; Liu N; Atkins WM; Lu AY
Drug Metab Dispos; 2000 Mar; 28(3):360-6. PubMed ID: 10681383
[TBL] [Abstract][Full Text] [Related]
8. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.
Wang YH; Jones DR; Hall SD
Drug Metab Dispos; 2005 May; 33(5):664-71. PubMed ID: 15689501
[TBL] [Abstract][Full Text] [Related]
9. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.
Patki KC; Von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2003 Jul; 31(7):938-44. PubMed ID: 12814972
[TBL] [Abstract][Full Text] [Related]
10. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
[TBL] [Abstract][Full Text] [Related]
11. Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes.
Yamazaki H; Urano T; Hiroki S; Shimada T
J Toxicol Sci; 1996 Nov; 21(4):215-26. PubMed ID: 8959645
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes.
Yamazaki H; Nakajima M; Nakamura M; Asahi S; Shimada N; Gillam EM; Guengerich FP; Shimada T; Yokoi T
Drug Metab Dispos; 1999 Sep; 27(9):999-1004. PubMed ID: 10460798
[TBL] [Abstract][Full Text] [Related]
13. In vitro complex formation and inhibition of hepatic cytochrome P450 activity by different macrolides and tiamulin in goats and cattle.
Zweers-Zeilmaker WM; Van Miert AS; Horbach GJ; Witkamp RF
Res Vet Sci; 1999 Feb; 66(1):51-5. PubMed ID: 10088712
[TBL] [Abstract][Full Text] [Related]
14. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.
Galetin A; Ito K; Hallifax D; Houston JB
J Pharmacol Exp Ther; 2005 Jul; 314(1):180-90. PubMed ID: 15784650
[TBL] [Abstract][Full Text] [Related]
15. Impact of Heterotropic Allosteric Modulation on the Time-Dependent Inhibition of Cytochrome P450 3A4.
Rougée LRA; Bedwell DW; Hansen K; Abraham TL; Hall SD
Drug Metab Dispos; 2023 Oct; 51(10):1372-1380. PubMed ID: 37524542
[TBL] [Abstract][Full Text] [Related]
16. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites.
Zhao XJ; Jones DR; Wang YH; Grimm SW; Hall SD
Xenobiotica; 2002 Oct; 32(10):863-78. PubMed ID: 12419016
[TBL] [Abstract][Full Text] [Related]
17. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
[TBL] [Abstract][Full Text] [Related]
18. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
[TBL] [Abstract][Full Text] [Related]
19. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
20. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
